Taken together, these results suggest that SGOL1 might serve as an indicator of ICI efficacy in ccRCC patients and a predictor of the clinical application of ICI therapy to better assist clinicians in treatment; however, additional experimental validation is needed. This evidence concerns the gene SGO1 and nonpapillary renal cell carcinoma.